Treatment Details – 4.8 months
|Patients: This Phase II study involved 10 patients with malignant mesothelioma.|
Treatment: The treatment consisted of the chemotherapy drug doxorubicin (adriamycin) (high-dose) with the drugs dexrazoxane (for cardio-protection), and GM-CSF (to lessen bone marrow toxicity).
Toxicity: One patient died of sepsis. In addition, grade 3-4 toxicities included hematologic, infection, esophagitis/dysphagia, and cardiac function. This study was terminated early due to excessive toxicity.
Results: No patient responded to treatment and the median overall survival was 4.8 months.
Correspondence: Michael P. Kosty, MD